🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

"Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"

RecruitingPhase 2, Phase 3Ages 18 Years - anyAllBeni-Suef University
NCT07684326 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate beneficial effects of using dapagliflozin in cirrhotic chronic liver disease patients. We hypnotized that the use of dapagliflozin will be associated with fewer need for large volume paracentesis hence better control of ascites, fewer need for ICU admissions, improvement of patient quality of life, better healthcare cost saving and reduced mortality rate.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patients 18 years of age and older with a diagnosis of liver cirrhosis with any degree of ascites that led to previous or recent hospital admission (determined by clinical findings and imaging) will be included in the study. Exclusion Criteria: 1. Child Pugh score ≥ 12 or MELD score \> 25. 2. Previous history of hypoglycemia or has a previous history of DKA. 3. Blood pressure less than 90/60 or need dose of midodrine \>15 mg/day. 4. Previous history of recurrent urinary tract infections (more than 2 infections in the last 6 months) or anatomic urologic defects that predispose to urinary tract infection. 5. Pregnant or lactating female patients. 6. Hypersensitivity to dapagliflozin. 7. eGFR \< 30 ml/min/1.73 m2 8. Had hepatocellular carcinoma or any malignancy. 9. Serum sodium level \< 125 mg/dl. 10. Portal vein thrombosis.
💊

What it tests

  • Dapagliflozin
📍

Where

1 site
Haram Hospital
Giza, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy